Cargando…

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma

Detalles Bibliográficos
Autores principales:	Schneller, Anja, Zojer, Niklas, Bolomsky, Arnold, Ludwig, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409038/ https://www.ncbi.nlm.nih.gov/pubmed/33910332 http://dx.doi.org/10.3324/haematol.2020.277152

Ejemplares similares

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2021)

Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment
por: Bolomsky, Arnold, et al.
Publicado: (2016)

Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation
por: Opydo, Małgorzata, et al.
Publicado: (2023)

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2015)

The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition
por: Peddaboina, Chander, et al.
Publicado: (2012)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
por: Dalafave, D.S., et al.
Publicado: (2010)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2018)

P873: CARFILZOMIB RESISTANCE IS ASSOCIATED WITH SIGNIFICANT DEREGULATION OF THE BH3 FAMILY PROTEINS
por: Schneller, A., et al.
Publicado: (2022)

MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
por: Bolomsky, Arnold, et al.
Publicado: (2020)

Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines
por: Abdul Rahman, Siti Fairus, et al.
Publicado: (2020)

Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
por: Bolomsky, Arnold, et al.
Publicado: (2021)

CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263
por: Huang, Tianlu, et al.
Publicado: (2019)

Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors
por: Senichkin, Viacheslav V., et al.
Publicado: (2021)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
por: Booher, Robert N., et al.
Publicado: (2014)

Computational design of an apoptogenic protein that binds BCL-xL and MCL-1 simultaneously and potently
por: Kim, Seonghoon, et al.
Publicado: (2022)

Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
por: Golla, Carolin, et al.
Publicado: (2021)

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
por: Melvold, Katrine, et al.
Publicado: (2021)

ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
por: Alcon, Clara, et al.
Publicado: (2021)

P864: CTPS1 IS A NOVEL THERAPEUTIC TARGET IN MYELOMA - SELECTIVE SMALL MOLECULE INHIBITION DELIVERS SINGLE AGENT ACTIVITY AND SYNERGISES WITH ATR INHIBITION
por: Pfeiffer, C., et al.
Publicado: (2022)

Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1
por: Mena, Salvador, et al.
Publicado: (2012)

The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells
por: Wang, Bin, et al.
Publicado: (2014)

Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells
por: Abdul Rahman, Siti Fairus, et al.
Publicado: (2022)

Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway
por: Luo, Fan, et al.
Publicado: (2021)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020)

Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1
por: Ow, Thomas J., et al.
Publicado: (2019)

Mcl-1 expression and JNK activation induces a threshold for apoptosis in Bcl-xL-overexpressing hematopoietic cells
por: Zhang, Yu, et al.
Publicado: (2016)

The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance
por: Fitzgerald, Marie-Claire, et al.
Publicado: (2023)

SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis
por: Ludwig, Heinz, et al.
Publicado: (2023)

MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL
por: Vikström, Ingela B, et al.
Publicado: (2016)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Delayed apoptosis by neutrophils from COPD patients is associated with altered bak, bcl-xl, and mcl-1 mRNA expression
por: Zhang, Jisong, et al.
Publicado: (2012)

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
por: Choudhary, G S, et al.
Publicado: (2015)

XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis
por: Zhu, Zhi-Chuan, et al.
Publicado: (2019)

Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

MicroRNA-377 Downregulates Bcl-xL and Increases Apoptosis in Hepatocellular Carcinoma Cells
por: Ge, Hongyan, et al.
Publicado: (2017)

Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas
por: Müller, Denise, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_navek6lfek6mqt213e7je88rbn